Related Experiment Video

Updated: Jun 23, 2026

Acute Myocardial Infarction in Rats
07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials

Massimo Volpe1, Giuliano Tocci, Sebastiano Sciarretta

  • 1Division of Cardiology, II Faculty of Medicine, University of Rome La Sapienza, Sant'Andrea Hospital, Rome, Italy. massimo.volpe@uniroma1.it

Journal of Hypertension
|April 22, 2009
PubMed
Abstract

Insights

Angiotensin II receptor blockers (ARBs) do not increase the risk of myocardial infarction (MI) compared to other antihypertensive drugs. This meta-analysis confirms ARBs are a safe option for managing cardiovascular conditions.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Antihypertensive medications are crucial for managing cardiovascular diseases.
  • Angiotensin II receptor blockers (ARBs) represent a significant class of drugs used for blood pressure control.
  • Assessing the comparative safety of ARBs regarding major adverse cardiovascular events is essential.

Purpose of the Study:

  • To evaluate the impact of Angiotensin II Receptor Blockers (ARBs) on the risk of myocardial infarction (MI).
  • To compare the incidence of cardiovascular death and all-cause mortality between ARB-based treatments and conventional therapies or placebo.
  • To determine the safety profile of ARBs across diverse clinical scenarios.

Main Methods:

  • A comprehensive meta-analysis was conducted on 20 major international randomized clinical trials.
  • Included trials involved 108,909 patients and compared ARBs against other antihypertensive drugs or placebo.
  • Data were analyzed for myocardial infarction incidence up to August 31, 2008.

Main Results:

  • No significant difference in MI risk was observed between ARB-based treatments and comparator groups (OR 1.008, 95% CI 0.950-1.069).
  • Subgroup analyses showed comparable MI risks across various conditions including hypertension, high cardiovascular risk, stroke, coronary disease, renal disease, and heart failure.
  • Specific comparisons against placebo, beta-blockers, diuretics, calcium channel blockers, and ACE inhibitors revealed no significant differences in MI risk.

Conclusions:

  • The use of Angiotensin II Receptor Blockers (ARBs) is associated with a myocardial infarction risk comparable to other antihypertensive medications.
  • ARBs demonstrate a similar safety profile concerning MI risk across a broad spectrum of clinical conditions.
  • This meta-analysis supports the use of ARBs as a safe therapeutic option in cardiovascular disease management.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...